David Hutton

A new technique will allow fast and non-invasive assessment of the physiological state of the retina. This could be a real breakthrough in the treatment of eye diseases.

Retina Technologies Inc. is working on a modular digital vision screening platform it says will provide vision testing for the early detection of eye disorders.

Jeff Cleland, PhD, CEO of Ashvattha, discusses safety data for an at-home subcutaneous injection option being developed for wet AMD and DME. The anti-VEGF candidate will enter a Phase 2 study later this year.

The challenge is for ophthalmology students to have seen a range of pupil abnormalities before they are in a cubicle with a real patient. One solution to this challenge may be virtual reality.

Presented at ARVO 2022, research from Mass Eye and Ear hopes to open a new avenue for therapies that are for helping treat patients that develop primary open angle glaucoma.

The Phase 3 registrational study is examining AR-15512, a differentiated, novel product candidate for the treatment of the signs and symptoms of Dry Eye Disease

According to the company, the ReCLAIM-2 study of elamipretide demonstrates a correlation between ellipsoid zone dysfunction and vision.

According to the company, a clinical trial evaluating Nyxol eye drops for night vision disturbances met FDA-agreed primary endpoint with subjects gaining 3 lines of low-contrast distance vision under dim light conditions compared to placebo.

According to the companies, Kala will receive $60 million in upfront payment, and could be eligible to receive additional sales-based milestone payments.

On this part two episode with Colin Carr, founder and CEO of CARR, we hear more about commercial real estate dos and don'ts when managing the space of your practice. Tune in now for the Q&A with Ophthalmology Times® executive editor, David Hutton.

The expansion includes the construction of the Jeffrey and Patricia Cole Building at Cole Eye Institute and renovation of the existing building.

In a patient survey, 66% of respondents said AI plays a large role in their diagnosis and treatment and thought it was important.

Two grants will be available, each offering $150,000 to scientists focusing on glaucoma research who have already received their first independent federal National Institutes of Health (NIH) grant and are collecting new and novel data to apply for a second R01.

An investigator at Anglia Ruskin University is leading work on an anti-cataract drug, which has had positive results in lab tests.

BRIM Biotechnology Inc. has entered into a new strategic partnership with Ora Inc. for the late-stage clinical development of lead drug candidate BRM421 for dry eye syndrome (DES).

Philip Ruzycki, PhD, receives a career development award that will provide $350,000 to support his laboratory over the next 4 years.

Formosa Pharmaceuticals, AimMax Therapeutics unveiled data from CPN-301, the first of two pivotal Phase 3 clinical studies of APP13007, a novel ophthalmic nanosuspension formulation of a potent corticosteroid, clobetasol propionate (0.05%).

A discovery by investigators at the National Eye Institute sheds light on tissue targeted by age-related macular degeneration and other diseases.

The Eye Van, operated by Vision Loss Rehabilitation Canada, is a mobile medical clinic that delivers eye care in northern Ontario communities where ophthalmology services aren't readily available.

The study found that if certain forms of nystagmus that are seen in patients, then there is a higher chance of poor binocular visual function, as well as higher interocular suppression.

The study evaluates three separate cases, each which experiences irreversible changes in their corneal structure caused by challenges in getting timely treatment due to various reasons, including insurance, lost to follow up, and the coronavirus pandemic.

The company is partnering with leading ophthalmology practices focused on improving patient outcomes. OMNY solutions are derived from electronic health record data and provide valuable information on the evolving treatment paradigm for patients with ophthalmic disease, including difficult to obtain insights on the rationale behind treatment decisions, and the impact of social determinants of health on care delivery and outcomes.

The American Academy of Ophthalmology applauded Congress for reaching the 290-consponsor milestone for the proposal. By reaching the two-thirds majority of bipartisan support in Congress, the bill is eligible for inclusion on the Consensus Calendar under new rules that were established in 2019.

Colin Carr, founder and CEO of CARR, chats with Ophthalmology Times' David Hutton in this part one episode of the EyePod. Carr hits on some hot real estate topics in the healthcare industry, including top mistakes healthcare providers make with their office space, how to decide whether you're going to purchase or lease, and how healthcare providers can save $100k or more on their next lease renewal.

As more and more practices embrace dark adaptation testing, AdaptDx technology has become a staple in primary eye care.

The company's VialConnect is an intuitive clinical trials management platform built for coordinators and investigators.

The companies will collaborate to commercialize therapeutic option in Greater China, South Korea and Select Southeast Asian Markets for the treatment of presbyopia, expanding access to long-acting, presbyopia-correcting eye drops for approximately 600 million patients.

The research, conducted by Boston Medical Center and Stanford University School of Medicine, found that most of the mistreatment came from patients and visitors.

The 10-week Flying Eye Hospital program will offer courses focusing on advanced glaucoma and simulation lectures for residents.

According to the company, the trial did not demonstrate efficacy on the key clinical endpoints and will not advance THR-687 to Part B of the trial. As a result, Oxurion will now shift its focus to the Phase 2 development program for THR-149, which recently demonstrated a compelling safety and efficacy profile for the treatment of patients with DME.